Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Biogen and Eisai Agree to Work Together on Alzheimer’s Therapy Aducanumab

A true 99.8% failure rate drug

Biogen and Eisai have deepened their partnership by agreeing to work together on the continued development of the Alzheimer’s therapy aducanumab (BIIB037), which targets harmful beta amyloid protein clusters.

The U.S. and Japanese companies are already collaborating on the development of elenbecestat (E2609) and BAN2401, which also target beta amyloid.

https://alzheimersnewstoday.com/2017/10/26/biogen-and-eisai-will-work-together-to-further-develop-alzheimers-therapy-aducanumab/